|
시장보고서
상품코드
1978134
바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
바이오마커 시장 규모는 2025년 2,092억 1,000만 달러에서 2026-2034년 CAGR 13.56%로 성장하여 2034년에는 6,570억 7,000만 달러에 이를 것으로 예측됩니다.
정밀의료와 질병 조기발견에 대한 수요 증가로 세계 바이오마커 시장은 강력한 성장세를 보이고 있습니다. 바이오마커는 질병의 진행과 치료 효과를 평가하기 위해 진단, 의약품 개발, 임상연구에 널리 활용되고 있습니다. 암, 심혈관 질환 등 만성질환의 유병률 증가가 시장 확대를 견인하고 있습니다.
주요 성장 요인으로는 유전체학, 단백질체학, 분자진단 기술의 발전을 들 수 있습니다. 제약회사들은 약물의 효능과 안전성을 향상시키기 위해 임상시험에서 바이오마커를 점점 더 많이 활용하고 있습니다. 또한, 연구개발에 대한 투자 확대와 생명공학 기업과 학계와의 협력이 혁신을 가속화하고 있습니다.
향후 전망으로는 인공지능(AI) 및 빅데이터 분석과의 통합이 시장에 긍정적인 영향을 미칠 것으로 예측됩니다. 개인 맞춤형 의료의 추진으로 바이오마커 기반 검사에 대한 수요는 더욱 증가할 것입니다. 개발도상국의 헬스케어 인프라 확충은 새로운 기회를 창출합니다. 진단 기술이 계속 발전함에 따라 바이오마커 시장은 장기적으로 성장할 것으로 예측됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 바이오마커 시장 : 유형별
제5장 세계의 바이오마커 시장 : 제품별
제6장 세계의 바이오마커 시장 : 용도별
제7장 세계의 바이오마커 시장 : 질환별
제8장 세계의 바이오마커 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
LSH 26.04.07The Biomarkers Market size is expected to reach USD 657.07 Billion in 2034 from USD 209.21 Billion (2025) growing at a CAGR of 13.56% during 2026-2034.
The Global Biomarkers Market is experiencing strong growth due to rising demand for precision medicine and early disease detection. Biomarkers are widely used in diagnostics, drug development, and clinical research to assess disease progression and treatment response. Increasing prevalence of chronic diseases such as cancer and cardiovascular disorders is fueling market expansion.
Key growth drivers include advancements in genomics, proteomics, and molecular diagnostics technologies. Pharmaceutical companies are increasingly utilizing biomarkers in clinical trials to improve drug efficacy and safety. Additionally, growing investments in research and development and collaborations between biotech firms and academic institutions are accelerating innovation.
Looking ahead, the market is expected to benefit from integration with artificial intelligence and big data analytics. Personalized medicine initiatives will further increase demand for biomarker-based testing. Expanding healthcare infrastructure in developing economies will create new opportunities. As diagnostic technologies continue to evolve, the biomarkers market is poised for long-term growth.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Type
- Safety Biomarkers
- Efficacy Biomarkers
- Predictive Biomarkers
- Surrogate Biomarkers
- Pharmacodynamic Biomarkers
- Prognostics Biomarkers
- Validation Biomarkers
By Product
- Consumable
- Services
- Software
By Application
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Others
By Disease
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
COMPANIES PROFILED
- F HoffmannLa Roche Ltd, Abbott Laboratories, Epigenomics AG, GE HealthCare Technologies Inc, Johnson Johnson Services Inc, Thermo Fisher Scientific Inc, BioRad Laboratories Inc, Siemens Healthineers AG, QIAGEN NV, Merck KGaA, PerkinElmer Inc, Agilent Technologies Inc, Eurofins Scientific SE
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Type
- 4.2. Safety Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Efficacy Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Surrogate Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.6. Pharmacodynamic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.7. Prognostics Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.8. Validation Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Product
- 5.2. Consumable Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Application
- 6.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Disease Risk Assessment Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL BIOMARKERS MARKET: BY DISEASE 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Disease
- 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.5. Immunological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Type
- 8.2.2 By Product
- 8.2.3 By Application
- 8.2.4 By Disease
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Type
- 8.3.2 By Product
- 8.3.3 By Application
- 8.3.4 By Disease
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Type
- 8.4.2 By Product
- 8.4.3 By Application
- 8.4.4 By Disease
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Type
- 8.5.2 By Product
- 8.5.3 By Application
- 8.5.4 By Disease
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Type
- 8.6.2 By Product
- 8.6.3 By Application
- 8.6.4 By Disease
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL BIOMARKERS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 F. Hoffmann-La Roche Ltd
- 10.2.2 Abbott Laboratories
- 10.2.3 Epigenomics AG
- 10.2.4 GE HealthCare Technologies Inc
- 10.2.5 Johnson & Johnson Services Inc
- 10.2.6 Thermo Fisher Scientific Inc
- 10.2.7 Bio-Rad Laboratories Inc
- 10.2.8 Siemens Healthineers AG
- 10.2.9 QIAGEN N.V
- 10.2.10 Merck KGaA
- 10.2.11 PerkinElmer Inc
- 10.2.12 Agilent Technologies Inc
- 10.2.13 Eurofins Scientific SE
